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Abstract: Angiogenic biomaterials are designed to promote vascularization and tissue regeneration.
Nanoparticles of bioactive materials loaded with drugs represent an interesting strategy to stimulate
osteogenesis and angiogenesis and to inhibit bone resorption. In this work, porcine endothelial pro-
genitor cells (EPCs), essential for blood vessel formation, were isolated and characterized to evaluate
the in vitro effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs),
which were designed to prevent osteoporosis. The expression of vascular endothelial growth factor
receptor 2 (VEGFR2) was studied in EPCs under different culture conditions: (a) treatment with
NanoMBGs or NanoMBG-IPs, (b) culture with media from basal, M1, and M2 macrophages previ-
ously treated with NanoMBGs or NanoMBG-IPs, (c) coculture with macrophages in the presence of
NanoMBGs or NanoMBG-IPs, and (d) coculture with M2d angiogenic macrophages. The endocytic
mechanisms for nanosphere incorporation by EPCs were identified using six different endocytosis
inhibitors. The results evidence the great potential of these nanomaterials to enhance VEGFR2
expression and angiogenesis, after intracellular incorporation by EPCs through clathrin-dependent
endocytosis, phagocytosis, and caveolae-mediated uptake. The treatment of EPCs with basal, M1,
and M2 macrophage culture media and EPC/macrophage coculture studies also confirmed the
angiogenic effect of these nanospheres on EPCs, even in the presence of phagocytic cells.
Keywords: endothelial progenitor cells; macrophages; mesoporous nanospheres; vascular endothe-
lial growth factor receptor 2; ipriflavone; endocytosis
1. Introduction
The vascular system plays an essential role in the efficient supply of oxygen and nutri-
ents needed to ensure the development of all tissues. Vascular structures can be formed
through vasculogenesis (de novo blood vessels created during embryonic development)
or angiogenesis (new vessels from a pre-existing vascular network) [1,2]. It is important
to highlight that different signals between vascular and nonvascular cells are essential to
initiate the angiogenic events that are required for regenerative processes [3,4]. In particular,
macrophages that infiltrate the damaged tissue secrete growth factors and other molecules
to stimulate angiogenesis depending on their phenotype and activation state [5,6]. It is
well known that macrophages are influenced by multiple microenvironmental stimuli
able to induce macrophage polarization toward M1 proinflammatory or M2 reparative
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phenotypes [7]. M1 macrophages are mainly induced by IFN-γ and bacterial lipopolysac-
charide (LPS), producing higher levels of proinflammatory cytokines and reactive oxygen
species (ROS) [8]. In contrast, M2 macrophages are induced by cytokines such as IL-4,
IL-10, IL-13, IL-21, and IL-33 and have an anti-inflammatory cytokine profile. Functionally,
M2 macrophages possess proangiogenic properties and promote tissue repair and wound
healing [9]. Depending on the activating stimulus, M2 macrophages can be divided into
four subsets: M2a, M2b, M2c, and M2d [10], which are induced by different cytokines and
produce specific molecules with different activities [8]. The fourth type of M2 macrophages,
M2d, is induced by agonists that target Toll-like receptors (TLRs) through the adenosine
receptor, followed by the suppression of proinflammatory cytokine production and the
induction of secretion of both anti-inflammatory cytokines and vascular endothelial growth
factor (VEGF) with proangiogenic properties [11,12].
VEGF acts on endothelial cells inducing angiogenesis [13] and regulates vascular
permeability [14]. The secretion of this factor by macrophages plays an important role in
wound healing, as well as in chronic inflammation and cancer [12]. Among the known
vascular endothelial growth factors (VEGFs) and receptors (VEGFRs), VEGF-A regulates
angiogenesis and vascular permeability by activating VEGFR1 and VEGFR2 receptors,
with VEGFR2 being the major signal transducer for angiogenesis through the PLCγ–PKC–
MAPK pathway [15]. VEGF-A also stimulates bone repair by promoting angiogenesis,
maturation of osteoblasts, ossification, and bone turnover [16]. Thus, osteogenesis is a
process coupled to vascularization during bone development and growth [17]. For this
reason, angiogenic biomaterials are designed to promote vascularization and optimize
bone regeneration [18–21]. In this context, nanoparticles of bioactive materials loaded
with different drugs represent an interesting strategy to promote bone regeneration by
stimulating osteogenesis and angiogenesis and inhibiting bone resorption [22,23]. Among
the drugs explored with this aim, ipriflavone (IP) prevents osteoporosis by inhibiting
the activity of osteoclasts [23,24] and stimulating the differentiation of pre-osteoblasts
into mature osteoblasts [25]. The administration of the drug with nanoparticles allows
significantly reducing the quantity of drug required to carry out the desire effect.
Since endothelial progenitor cells (EPCs) are involved in blood vessel formation, es-
sential for tissue regeneration, porcine EPCs have been used in this work to evaluate their
response to ipriflavone-loaded mesoporous bioactive nanospheres, designed to stimulate
osteogenesis. These nanospheres (NanoMBGs) have shown excellent in vitro behavior
in previous studies with bone cells [23,25]. The expression of VEGFR2, directly related
to angiogenesis, has been analyzed in EPCs treated with these nanospheres considering
the possible modulating role of macrophages, depending on their phenotype and acti-
vation state. With this objective, the actions of NanoMBGs without or with ipriflavone
(NanoMBG-IPs) and macrophage mediators on angiogenesis were evaluated by assessing
VEGFR2 expression, under different conditions: (a) EPCs in monoculture treated with
NanoMBGs or NanoMBG-IPs, (b) EPCs treated with conditioned media from basal, M1,
and M2 macrophages previously treated with NanoMBGs or NanoMBG-IPs, (c) EPCs
cocultured with macrophages in the presence of NanoMBGs or NanoMBG-IPs, and (d)
EPCs cocultured with M2d angiogenic macrophages. On the other hand, the endocytic
mechanisms via which these nanospheres are incorporated by EPCs were identified using
six endocytosis inhibitors (i.e., wortmannin, genistein, cytochalasin B, cytochalasin D,
phenylarsine oxide, and chlorpromazine) before the addition of NanoMBGs labeled with
fluorescein isothiocyanate (FITC-NanoMBGs). Overall, the present work will contribute to
the knowledge of the incorporation mechanisms of these ipriflavone-loaded nanospheres
into EPCs to promote tissue regeneration and the modulatory role played by macrophages
as main cells of the innate immune response to this kind of nanomaterial.
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2. Materials and Methods
2.1. Preparation, Characterization, Labeling with FITC, and Loading with Ipriflavone of
Mesoporous Nanospheres
Mesoporous nanospheres (NanoMBGs) with nominal chemical composition 75 SiO2/20
CaO/5 P2O5 (mol.%) were synthesized, characterized, and labeled with fluorescein isothio-
cyanate (FITC-NanoMBGs) as previously described [23,25]. Briefly, 80 mg of poly(styrene)-
block-poly(acrylic acid) and 160 mg of hexadecyl trimethyl ammonium bromide (CTAB)
were dissolved in tetrahydrofurane (16 mL) and water/ammonia (74 mL/2.4 mL), re-
spectively, and mixed together under vigorous magnetic stirring. Subsequently, 25 µL of
triethylphosphate (TEP) and 0.52 mL of tetraethoxysilane (TEOS) previously dissolved
in ethanol were added dropwise under stirring. Then, 125 mg of Ca(NO3)2·4H2O in
1.6 mL of water was also added and stirred for 10 min more. After stirring for 24 h, the
resulting product was collected by centrifugation and treated at 550 ◦C to remove the
organic template.
The nanoparticles were subsequently labeled with FITC by dissolving 0.6 mg of FITC
and 44.3 µL of aminopropyl triethoxysilane (APTS) in 0.5 mL of ethanol. This solution was
added dropwise to 50 mg of nanoparticles previously suspended in toluene and left to
react at 80 ◦C for 12 h under nitrogen atmosphere.
Ipriflavone-loaded nanoparticles (NanoMBG-IPs) were prepared by dissolving 250 mg
of ipriflavone in 3 mL of acetone. Thereafter, 100 mg of previously dried nanoparticles
treated at 100 ◦C for 24 h were added to the solution and gently stirred in an incubator at
37 ◦C with a rotation speed of 100 rpm for 12 h. After this period, the nanoparticles were
collected by filtration under vacuum using a polyamide filter.
For morphological characterization of nanoparticles, scanning electron microscopy
(SEM) and transmission electron microscopy (TEM) images were collected with a JEOL
F-6335 microscope and a JEOL-1400 microscope (JEOL, Tokyo, Japan), respectively. Thermo-
gravimetric analysis was carried out with a TG/DTA Seiko SSC/5200 thermobalance. The
thermogram was obtained from 100 ◦C to 650 ◦C using a platinum crucible and α-Al2O3 as
a reference.
2.2. Obtention and Culture of Endothelial Progenitor Cells (EPCs)
Endothelial progenitor cells (EPCs) were obtained as previously described [26,27].
Briefly, whole pig blood was diluted (1:1) in phosphate-buffered saline (PBS) with 0.1% of
bovine serum albumin (BSA) and 0.6% of sodium citrate. Mononuclear cells (MNCs) were
isolated using a density gradient formed with Histopaque-1077 solution (Sigma–Aldrich
Corporation, St. Louis, MO, USA) in AccuspinTM tubes (Sigma–Aldrich Corporation, St.
Louis, MO, USA). The samples were centrifuged at 800× g for 30 min at room temperature.
The MNC layer was carefully collected and seeded in Endothelial Growth Medium (EGM-
2, Sigma–Aldrich Corporation, St. Louis, MO, USA) in F75 polystyrene culture flasks
(Corning Inc., Corning, NY, USA) at a density of 2–3 × 105 cells/cm2 under a CO2 (5%)
atmosphere and at 37 ◦C. The culture medium was replaced at 96 h and then every
48 h until confluence. Confluent cultures of EPCs were maintained in EGM-2 until cells
acquired the cobblestone morphology characteristic of mature endothelial cells. After
confirmation of their endothelial phenotype as described below (Section 2.3), cells were
cultured in EGM-2 with or without nanospheres for several times in different culture
plates and at different cell densities according to the type of experiment: (a) in 12-well
culture plates (Corning Inc., Corning, NY, USA) at a density of 105 cells/well during
24 h for the subsequent incorporation of FITC-labeled NanoMBGs for 30, 60, and 90 min
(Section 2.4) and (b) in six-well culture plates (Corning Inc., Corning, NY, USA) at a density
of 15 × 103 cells/well during 10 days for evaluation of VEGFR2 expression in different
conditions (Sections 2.5–2.7).
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2.3. Phenotypic Characterization of EPCs
After the obtention of EPCs as described above, the following markers were evaluated
to assess their differentiation toward a mature endothelial phenotype after 23 and 30 days
of culture in EGM-2:
- CD31, transmembrane receptor also known as platelet endothelial cell adhesion
molecule-1, PECAM-1 [28];
- CD34, transmembrane cell surface glycoprotein selectively expressed within the
hematopoietic system on stem and progenitor cells [29];
- eNOS, endothelial nitric oxide synthase, responsible for the endothelial production of
NO [30];
- vWF, von Willebrand factor, glycoprotein produced by endothelial cells and megakary-
ocytes [31];
- VEGFR2, VEGF receptor 2, whose expression is restricted to endothelial cells, mono-
cytes, and hematopoietic precursors [32].
For flow cytometry studies, 106 cells were used to carry out the identification of
each of these markers by immunostaining with corresponding antibodies. The antibodies
used in this study were as follows: anti-CD31 (TLD-3A12, ab64543, Abcam, Cambridge,
UK), anti-CD34 (EP373Y, ab81289, Abcam, Cambridge, UK), anti-eNOS (M221, ab76198,
Abcam, Cambridge, UK), anti-vWF (ab6994, Abcam, Cambridge, UK), and anti-VEGFR2
(ab2349, Abcam, Cambridge, UK). Two secondary antibodies were used, one conjugated
with DyLight 633 (IgG (H + L) goat anti-rabbit DyLight® 633, Invitrogen, Carlsbad, CA,
USA) and the other with Alexa 488 (IgG (H + L) Highly cross-adsorbed goat anti-mouse
Alexa Fluor® Plus 488, Invitrogen, Carlsbad, CA, USA). All antibodies were prepared in
normal goat serum (NGS) at 2% for use. The final antibody concentrations were 10 µg/mL
for flow cytometry and 5 µg/mL for confocal microscopy, unless specifically prescribed by
the supplier. In the case of intracellular markers (eNOS and vWF), the cells were previously
permeabilized with 0.25% saponin for 10 min at 4 ◦C before adding the antibodies, and
saponin at 0.25% was maintained at all subsequent steps of immunolabeling. To prevent
nonspecific binding, cells were incubated in 10% PBS/NGS for 10 min at room temperature.
After centrifugation, 300 µL of the corresponding primary antibody was added to the pellet,
incubating the tubes for 30 min at room temperature in darkness. Then, 700 µL of 1%
PBS/BSA was added for 10 min at room temperature for washing and, after centrifugation,
the pellet was incubated with 300 µL of the corresponding secondary antibody for 30 min
at room temperature in darkness. Finally, the pellet was washed with 700 µL of 1%
PBS/BSA for 10 min at room temperature, centrifuged, and resuspended in 300 µL of PBS.
The resulting EPC suspensions labeled with the different antibodies were analyzed in a
FACScalibur Becton Dickinson flow cytometer. The fluorescence of Alexa Fluor 488 was
excited at 488 nm and measured at 519 nm. The fluorescence of DyLight 633 was excited at
638 nm and measured at 658 nm.
For confocal microscopy studies, EPCs were cultured on glass coverslips under the
above conditions, fixed with 0.5 mL of 4% paraformaldehyde for 10 min at room temper-
ature and washed with PBS three times. For intracellular labeling, cell membranes were
permeabilized with 0.5 mL of 70% ethanol at 4 ◦C for 10 min and washed with PBS three
times. To avoid nonspecific binding, samples were incubated with 0.5 mL of 10% PBS/NGS
for 10 min at room temperature and washed with PBS three times. Then, 50 µL of the
corresponding primary antibody was added in 2% PBS/NGS at a final concentration of
5 µg/mL for 1 h at room temperature. After that, samples were washed three times with
0.5 mL of 2% PBS/NGS, and 50 µL of the corresponding secondary antibody was added
to a final concentration of 5 µg/mL. After washing three times with 0.5 mL of PBS, 3 µM
4′-6-diamidine-2′-phenylindole (DAPI, Molecular Probes, Eugene, OR, USA) was added for
5 min, and the glass coverslips were mounted on slides with ProLongTM Gold (Invitrogen,
Carlsbad, CA, USA). Samples were then observed on a Leica SP2 AOBS multiphoton
confocal laser microscope. DAPI fluorescence was excited at 405 nm and measured at
420–480 nm. The fluorescence of Alexa FluorTM was excited at 488 nm and measured
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at 519 nm. The fluorescence of DyLightTM 633 was excited at 638 nm and measured at
658 nm.
2.4. Analysis of the Incorporation of FITC-Labeled NanoMBGs by EPCs and Identification of
Endocytic Mechanisms
EPCs cultured in EGM-2 for 24 h were exposed to 50 µg/mL of FITC-NanoMBGs for
30, 60, and 90 min. After that, cells were harvested with trypsin-EDTA (0.25%), and FITC-
NanoMBG incorporation was quantified through flow cytometry. The FITC-NanoMBG
fluorescence was detected in a FACScalibur Becton Dickinson flow cytometer with a
530/30 filter, exciting the sample at 488 nm. Data acquisition and flow cytometric analysis
conditions were set through negative and positive controls using the CellQuest Program of
Becton Dickinson and maintained for all measurements. For each sample, 104 cells were
analyzed to ensure a correct statistical significance.
For confocal microscopy studies, EPCs were cultured on circular glass coverslips
in the presence of 50 µg/mL of FITC-NanoMBGs for 24 h. Afterward, cells were fixed
with paraformaldehyde (3.7%) and permeated with 500 µL of Triton-X100 (0.1% in PBS).
After 20 min of incubation with BSA (1% in PBS), samples were stained with rhodamine–
phalloidin 1:40 (100 µL), washed with PBS, and stained with 100 µL of 3 µM DAPI. Finally,
samples were observed by using an Olympus FV1200 confocal laser scanning microscope.
FITC fluorescence was excited at 488 nm and measured at 491–586 nm. Rhodamine
fluorescence was excited at 546 nm and detected at 600–620 nm. DAPI fluorescence was
excited at 405 nm and detected at 420–480 nm.
To identify the endocytic mechanisms via which FITC-NanoMBGs were incorporated
by EPCs, the treatment with six specific endocytosis inhibitors was carried out before
adding the nanoparticles, maintaining the cells for 2 h under the conditions described
above. The endocytosis inhibitors were as follows: 23 µM wortmannin (Enzo Life Sciences,
Barcelona, Spain), 3.7 µM genistein (Enzo Life Sciences, Barcelona, Spain), 20 µM cytocha-
lasin B (MP Biomedicals, Eschwege, Germany), 4 µM cytochalasin D (MP Biomedicals,
Eschwege, Germany), 3.7 µM phenylarsine oxide (PAO, Sigma–Aldrich Corporation, St.
Louis, MO, USA), and 30 µM chlorpromazine (Enzo Life Sciences, Barcelona, Spain). Then,
50 µg/mL of FITC-NanoMBGs were added to the medium and cells were maintained for
30 min under the conditions described above. Finally, cells were collected with trypsin-
EDTA (0.25%), and the FITC-NanoMBG incorporation in each case was quantified by flow
cytometry. Controls without inhibitors were carried out in parallel. The dose of each
inhibitor was chosen according to previous studies [25,33–37].
2.5. Evaluation of VEGFR2 Expression in EPCs after Treatment with NanoMBGs and
NanoMBG-IPs
EPCs were cultured in the presence of 50 µg/mL of unloaded and IP-loaded nanospheres
(NanoMBGs and NanoMBG-IPs, respectively) for 10 days under the conditions described
above, refreshing the culture medium with nanospheres every 3 days. To evaluate the
intracellular action of ipriflavone on the differentiation of EPCs, cells were harvested with
trypsin-EDTA (0.25%), and VEGFR2 expression was quantified by flow cytometry as a specific
marker of EPC differentiation after immunostaining with the corresponding antibody as
described above (Section 2.3).
2.6. Culture, M1/M2 Stimulation, and Treatment of RAW 264.7 Macrophages with NanoMBGs
and NanoMBG-IPs. Treatment of EPCs with Macrophage Conditioned Media to Evaluate
VEGFR2 Expression
RAW 264.7 macrophages (American Type Culture Collection, ATCC) were seeded in
six-well culture plates (Corning Inc., Corning, NY, USA), at a density of 105 cells/mL, in
2 mL of Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS, Gibco, BRL), 1 mM L-glutamine (BioWhittaker Europe, Verviers, Belgium),
penicillin (200 µg/mL, BioWhittaker Europe, Belgium), and streptomycin (200 µg/mL,
BioWhittaker Europe, Belgium) at 37 ◦C under a CO2 (5%) atmosphere. Cells were
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treated for 24 h in the absence or in the presence of 50 µg/mL of unloaded and IP-loaded
nanospheres (NanoMBGs and NanoMBG-IPs, respectively) in basal or stimulated condi-
tions in order to induce the polarization of macrophages toward M1 or M2 phenotypes. To
induce the M1 phenotype, macrophages were culture in the presence of E. coli lipopolysac-
charide (LPS, 250 ng/mL, Sigma-Aldrich Corporation, St. Louis, MO, USA) [38]. To induce
the M2 phenotype, macrophages were culture in the presence of interleukin-10 (IL-10,
40 ng/mL, BioLegend, San Diego, CA, USA) [39]. After these treatments, media were
aspirated and kept at −20 ◦C until use. EPCs were cultured in six-well culture plates
(15 × 103 cells/well) and treated for 10 days with these conditioned media from basal, M1,
and M2 macrophages to evaluate their effects on VEGFR2 expression by flow cytometry as
described above (Section 2.3). The conditioned medium was changed every 3 days.
2.7. Coculture of EPCs and RAW 264.7 Macrophages in the Presence of NanoMBGs and
NanoMBG-IPs. Evaluation of VEGFR2 Expression in EPCs and CD206 Expression in RAW 264.7
Macrophages
EPCs were seeded in six-well culture plates at a density of 15 × 103 cells/well. Simul-
taneously, RAW 264.7 cells were seeded in transwell inserts (0.4 µm pore size, Corning Inc.,
Corning, NY, USA) at a density of 15 × 103 cells/transwell in 1.3 mL of the same culture
medium and placed into the six-well culture plates containing seeded EPCs (Scheme 1).
For coculture, we used a medium composed of 50% DMEM and 50% EGM-2, having previ-
ously verified that both cell types proliferate adequately. These cocultures were carried
out in the presence or the absence of 50 µg/mL of NanoMBGs without or with ipriflavone
(NanoMBG-IPs) for 7 days at 37 ◦C under a CO2 (5%) atmosphere. In parallel, EPCs and
macrophages were cultured alone in wells and transwell inserts, respectively, as controls.
After coculturing, EPCs and macrophages were washed with PBS, harvested using 0.25%
trypsin-EDTA solution and cell scrapers, respectively, centrifuged at 310× g for 10 min,
and resuspended in PBS for the analysis of the expression of VEGFR2 in EPCs and CD206
in RAW 264.7 macrophages by flow cytometry. VEGFR2 expression, as a specific marker
of EPCs differentiation into mature endothelium, was evaluated by flow cytometry as
described above (Section 2.3). CD206 expression, as a specific marker of M2 macrophage
phenotype [40], was quantified by flow cytometry as described below. After detachment
and centrifugation, macrophages were incubated in 45 µL of staining buffer (PBS, 2.5%
FBS Gibco, BRL and 0.1% sodium azide, Sigma-Aldrich Corporation, St. Louis, MO, USA)
with 5 µL of normal mouse serum inactivated for 15 min at 4 ◦C in order to block the Fc
receptors on the macrophage plasma membrane, before adding the primary antibody, and
to prevent nonspecific binding. Then, cells were incubated with FITC anti-mouse CD206
(15 µg/mL, BioLegend, San Diego, CA, USA) for 30 min in the dark. Labeled cells were
analyzed using a FACSCalibur flow cytometer. FITC fluorescence was excited at 488 nm
and measured with a 530/30 band pass filter.
The effects of NanoMBGs and NanoMBG-IPs on the expression of VEGFR2 and
CD206 in EPC/macrophage cocultures were compared with the expression of these spe-
cific markers when EPCs were cocultured with M2d angiogenic macrophages. M2d an-
giogenic macrophages were obtained from RAW 264.7 macrophages treated with 5’-N-
ethyl-carboxamido-adenosine (NECA, 1 µM, MedChemExpress, Monmouth Junction, NJ,
USA)/E. coli LPS (100 ng/mL, Sigma-Aldrich Corporation, St. Louis, MO, USA) [12].
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Scheme 1. Cocultures of endotheli l progenitor cells (EPCs) and RAW 264.7 macrophages in the
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2.8. Statistics
Results were expressed as the means of three identical experiments with their corre-
sponding standard deviations, analyzed using the 22nd version of Statistical Package for
the Social Sciences (SPSS). Statistical comparisons were carried out by one-way analysis of
variance (ANOVA), and Scheffé and Games–Howell tests were used for post-hoc analysis
of differences between study groups, considering p < 0.05 as statistically significant.
3. Results and Discussion
3.1. Characterization of Mesoporous Nanospheres
Figure 1a,b show representative SEM and TEM images obtained from Nano-MBG
samples, i.e., before loading with ipriflavone. The particles showed an external spherical
morphology (Figure 1a) and a mesoporous structure consisting of a hollow core surrounded
by a radial mesoporous shell (Figure 1b). Subsequent TEM observations after the loading
process indicated a significant loss of mesoporous structure because of drug loading process
(Figure 1c). The am unt of loaded iprifl vone was 19.3% ± 1.7% (wt.%) as determined
by thermogravimetric analysis, pointing out that the mesoporous structure introduced by
the organic templates was appropriate for the use of Nano-MBG particles as matrices for
loading this antiosteoporotic drug.
3.2. Differentiation and Phenotypic Characterization of EPCs
EPCs a e considered a promising cell strategy fo tissue engineering applications
due to their highly proliferativ and an thrombogenic behavior [41,42]. This cell type
can be easily obtained from peripheral blood [26,27], and it is very appropriate as an
in vitro experimental model for the study of the angiogenic potential of different bioma-
terials [19,21,43,44]. In this work, after isolating EPCs from porcine peripheral blood and
culturing for 23 and 30 days in EGM-2 differentiation medium, the expression of CD31,
CD34, VEGFR2, eNOS, and vWF, as endothelial phenotype markers, was analyzed by
flow cytometry.
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images of Nano-MBGs before loading with ipriflavone (b) and after loading with iproflavone (Nano-
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As observed in Figure 2, the expression of the endothelial phenotype markers signifi-
cantly increased in a time-dependent manner, thus indicating the correct differentiation of
the EPCs toward a mature endothelial phenotype. When comparing the values obtained
at 23 and 30 days, VEGFR2 and vWF (Figure 2B) showed more significant increases in
comparison to the other markers CD31, CD34, and eNOS (Figure 2A). According to these
results and considering that the expression of VEGFR2 is directly related to angiogenesis,
VEGFR2 was chosen as a reference marker to assess the potential angiogenic effect of
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ipriflavone-loaded nanospheres (NanoMBG-IPs) on EPCs after 30 days of differentiation,
as well as the modulating role of M1 and M2 macrophages on them.
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Figure 2. Phenotypic characterization of EPCs in culture. The expression of (A) CD31, CD34, and eNOS and (B) VEGFR2
and vWF, was evaluated in EPCs as endothelial phenotype markers by immunofluorescence labeling and flow cytometry
after 23 and 30 days of differentiation. In each sample, 10,000 cells were analyzed. Statistical significance: *** p < 0.005.
3.3. Incorporation of FITC-Labeled N oMBGs by EPCs and Endocytic Mechanisms
To evaluate the incorporation of NanoMBGs by EPCs, these nanospheres were la-
beled with FITC. EPCs were cultured for 24 h and then treated with 50 µg/mL of FITC-
NanoMBGs for 30, 60, and 90 min in order to quantify the amount of intracellular uptake
of this nanomaterial by flow cytometry. Figure 3A shows the intracellular fluorescence
intensity of EPCs after this treatment, evidencing a fast and time-dependent uptake of
FITC-NanoMBGs, in agreement with previous studies carried out with these nanospheres
in other cell types [25,45]. Moreover, confocal microscopy studies were carried out after
treatment of EPCs with 50 µg/mL of FITC-NanoMBGs for 24 h to observe the intracellular
uptake of this nanomaterial and to evaluate if its i corporation could damage the cytoskele-
ton structure. Figure 4 shows the abundance of nanospheres into the cytoplasm of EPCs
and the integrity of their morphology without cytoskeleton alterations after the uptake.
On the other hand, to identify the endocytic mechanisms via which these nanospheres
are incorporated by EPCs, six endocytosis inhibitors (i.e., wortmannin, genistein, cytocha-
lasin B, cytochalasin D, phenylarsine oxide, and chlorpromazine) were used before the
addition of FITC-NanoMBGs. Since these agents affect different proteins, thus blocking spe-
cific endocytic mechanisms, their use indirectly provides information on the pathways that
could be involved in the entry of these nanospheres. In this sense, when the inhibitor used
decreases the uptake of nanospheres, the blocked mechanism constitutes an entry pathway.
In contrast, if the inhibitor does not decrease the incorporation of the nanospheres, that
specific mechanism that has been blocked by the inhibitor is not involved in the nanosphere
entry. The dose of each inhibitor was chosen according to previous studies [25,33–37]. As it
can be observed in Figure 3B, all inhibitors except cytochalasin D significantly decreased the
incorporation of FITC-NanoMBGs, demonstrating that this nanomaterial is incorporated
into EPCs via several uptake mechanisms.
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Figure 3. (A) Incorporation of FITC-NanoMBGs by EPCs evaluated by flow cytometry. Fluorescence intensity of EPCs with
intracellular FITC-NanoMBGs after treatment with 50 µg/mL for different times (30, 60, and 90 min). Statistical significance:
*** p < 0.005. (B) Effects of specific endocytosis inhibitors on FITC-NanoMBG incorporation by EPCs. EPCs were treated
for 2 h with each inhibitor before treatment with 50 µg/mL FITC-NanoMBGs for 30 min. FITC-NanoMBG incorporation
in each case was quantified by flow cytometry. Control cells without inhibitors were carried out in parallel. C = control
cells, W = cells treated with wortmannin, G = cells treated with genistein, CB = cells treated with cytochalasin B, CD =
cells treated with cytochalasin D, PAO = cells treated with phenylarsine oxide, Chl = cells treated with chlorpromazine.
Statistical significance: * p < 0.05, *** p < 0.005.
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Figure 4. Incorporation of FITC-NanoMBGs by EPCs observed by confocal microscopy. Images of
EPCs after 24 h of incubation with 50 µg/mL of FITC-NanoMBGs. Nuclei were stained with DAPI
(blue), F-actin filaments were stained with rhodamine-phalloidin (red), and FITC-NanoMBGs are
observed in green.
Specifically, wortmannin inhibits phosphoinositide 3-kinase (PI3K) and phosphoinosi-
tide 4-kinase (PI4K) [33], which play important roles in cell adhesion, proliferation, motility,
apoptosis, and cytoskeletal organization, impacting the phagocytosis mechanisms [46]. On
the other hand, genistein produces inhibition of Src tyrosine kinases and affects clathrin-
independent endocytosis mediated by caveolae [36]. Since wortmannin and genistein
significantly decreased the incorporation of FITC-NanoMBGs by EPCs (p < 0.005), we can
conclude that phagocytosis a d ca olae-mediated uptake ar mechanisms involved in the
uptake of these nanospher s by this cell typ .
Cytochalasins B and D inhibit macropinocytosis via actin polymerization blockage,
preventing microfilament action [35,36]. These inhibitors slightly decreased the nanoma-
terial uptake, but only the effect of cytochalasin B was significant at these experimental
conditions (p < 0.05). Similar results were obtained in a previous study, when the effect of
these inhibitors on FITC-NanoMBG incorporation by pre-osteoblasts was analyzed [25].
Phenylarsine oxide (PAO), an inhibitor of clathrin-dependent endocytosis [34,47,48], and
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chlorpromazine, also an inhibitor of clathrin-mediated endocytosis [35], induced more
significantly pronounced effects than the other agents, evidencing that clathrin-dependent
endocytosis is the main entry mechanism of FITC-NanoMBGs into EPCs.
3.4. Effects of NanoMBGs and NanoMBG-IPs on VEGFR2 Expression in EPCs. Modulating Role
of M1 and M2 Macrophages
After demonstration of an efficient intracellular incorporation of FITC-NanoMBGs into
EPCs by flow cytometry and confocal microscopy and elucidation of the entry pathways
of this nanomaterial into these cells, the effect of unloaded (NanoMBGs) and ipriflavone-
loaded nanospheres (NanoMBG-IPs) on the differentiation process of EPCs was analyzed
by studying VEGFR2 expression as a specific marker of endothelial differentiation. As
it can be observed in Figure 5A, the uptake of NanoMBGs and NanoMBG-IPs induced
significant increases in the percentage of VEGFR2+ EPCs compared to control cells after
10 days of treatment with 50 µg/mL of these nanomaterials. These results evidence the
ability of these mesoporous nanospheres, even without the drug, to stimulate VEGFR2
expression in EPCs and highlight their potential action on angiogenesis. This effect was
more pronounced with NanoMBG-IPs than with NanoMBGs, thus indicating the efficient
intracellular release of IP from these nanospheres and its positive in vitro effect on the
differentiation of EPCs toward more mature endothelial phenotypes. These data are in
consonance with results obtained by us and other authors in relation to the stimulation of
osteogenesis and angiogenesis by delivering Si ions and functional drugs from mesoporous
silica nanospheres [23,25,49]. Moreover, since macrophages secrete growth factors and
other molecules to stimulate angiogenesis depending on their phenotype and activation
state [5,6], we wanted to assess the modulating role of conditioned media from basal,
M1, and M2 macrophages on the differentiation of EPCs and the effects of the previous
24 h treatment of these macrophages with 50 µg/mL of NanoMBGs and NanoMBG-IPs.
Figure 5B–D show the percentages of VEGFR2+ EPCs after 10 days in the presence of the
following macrophage conditioned media: (B) treatment with culture media from basal
macrophages previously cultured for 24 h in the absence or in the presence of 50 µg/mL of
NanoMBGs or NanoMBG-IPs; (C) treatment with culture media from E. coli LPS-stimulated
M1 macrophages previously cultured for 24 h in the absence or in the presence of 50 µg/mL
of NanoMBGs or NanoMBG-IPs; (D) treatment with culture media from IL-10-stimulated
M2 macrophages previously cultured for 24 h in the absence or in the presence of 50 µg/mL
of NanoMBGs or NanoMBG-IPs.
The treatment of EPCs for 10 days with culture media from basal, M1, and M2
macrophages previously cultured for 24 h in the absence of nanospheres induced signifi-
cant increases in the percentage of VEGFR2+ EPCs (control bar in Figure 5B–D) compared to
control cells (control bar in Figure 5A). However, these increases were less pronounced than
the increments produced by the direct treatment of EPCs with NanoMBGs or NanoMBG-IPs
(NanoMBGs bar and NanoMBG-IPs bar in Figure 5A). The similar effect of culture media
from control macrophages in basal conditions or in both stimulated conditions (stimulation
towards M1 or towards M2) demonstrates that the modulatory effect of macrophages on
EPCs differentiation is related to macrophage intervention per se, independently of the
existence or not of stimuli and the type of stimulus used in these assays. When we inves-
tigated the effect of conditioned media from macrophages previously treated with both
NanoMBGs and NanoMBG-IPs (NanoMBGs bar and NanoMBG-IPs bar in Figure 5B–D),
similar results were obtained, thus indicating that the pretreatment of macrophages with
these nanospheres under basal or stimulated conditions does not change the effect induced
by macrophage-released mediators on VEGFR2 expression. Previous studies evidenced
that these NanoMBGs did not induce macrophage polarization toward the M1 proinflam-
matory phenotype, favoring the M2 reparative phenotype and increasing the macrophage
response capability against stimuli such as LPS and IL-4 [23].
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Figure 5. Effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs) on VEGFR2 expression in
EPCs and modulating role of M1 and M2 macrophages. Percentages of VEGFR2+ EPCs were analyzed by flow cytometry
after 10 days of treatment under the following conditions: (A) direct treatment with 50 µg/mL of either NanoMBGs or
NanoMBG-IPs; (B) treatment with culture media of basal macrophages previously cultured for 24 h in the absence or in
the presence of 50 µg/mL of NanoMBGs or NanoMBG-IPs; (C) treatment with culture media of E. coli LPS-stimulated M1
macrophages previously cultured for 24 h in the absence or in the presence of 50 µg/mL of NanoMBGs or NanoMBG-IPs;
(D) treatment with culture media of IL-10-stimulated M2 macrophages previously cultured for 24 h in the absence or in the
presence of 50 µg/mL of NanoMBGs or NanoMBG-IPs. Statistical significance: *** p < 0.005 (comparisons with control
EPCs directly treated with either NanoMBGs or NanoMBG-IPs), ### p < 0.005 (comparison with EPCs in the same culture
conditions without macrophage conditioned medium).
3.5. Effects of anoMBGs and NanoMBG-IPs on VEGFR2 and CD206 Expression in Cocultured
EPCs and RAW 264.7 Macrophages, Respectively
Next, we analyzed the effect of NanoMBGs and NanoMBG-IPs in cocultures of EPCs
and RAW 264.7 macrophages, so that they could maintain communication with each
other. These cocultures were carried out in the presence or the absence of 50 µg/mL of
NanoMBGs or NanoMBG-IPs for 7 days. After coculture, EPCs and macrophages were
harvested separately for the analysis of VEGFR2 and CD206 expression in EPCs and
RAW 264.7 macrophages, respectively. EPCs and macrophages cultured alone served as
controls. The expression of these specific markers when EPCs were cocultured with M2d
angiogenic macrophages obtained from RAW 264.7 macrophages treated with 1 µM NECA,
and 100 ng/mL of E. coli LPS was als used for comparison.
As can be observed in Figure 6, the coculture of EPCs with control RAW macrophages
or M2d angiogenic macrophages produced a decrease or increase in VEGFR2 expression,
respectively, when compared to monocultured EPCs. Although these changes were not
statistically significant, they are in line with previous results by other authors who demon-
strated that anti-inflammatory M2, but not proinflammatory M1 macrophages, promote
angiogenesis in vivo [50,51].
The presence of either NanoMBGs or NanoMBG-IPs in the EPC/RAW coculture
induced pronounced and significant increases in the percentage of VEGFR2+ EPCs, in
agreement with results obtained with monocultured EPCs (Figure 5). Again, these data
demonstrate the angiogenic effect of this nanomaterial, regardless of the presence of
ipriflavone. A nonsignificant incr ase was observed in the presence of NanoMBG-IPs
compared to NanoMBG; however, it appears that, under these coculture conditions, the
action of the drug is masked due to the presence of macrophages in the coculture, which
also incorporate the nanospheres and do not allow the effect of the drug to be appreciated.
Under these experimental conditions, only the angiogenic effect of the nanomaterial itself
is evident. These results are in agreement with the data in Figure 5, which shows a similar
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effect of the conditioned media from macrophages previously treated with both NanoMBGs
and NanoMBG-IPs on VEGFR2 expression in EPCs, thus indicating that the presence of the
drug in the nanospheres does not change the effect of macrophages on VEGFR2 expression
by EPCs.




Figure 6. Effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs) 
on VEGFR2 expression in EPCs cocultured with RAW 264.7 macrophages. Percentages of 
VEGFR2+ EPCs after 7 days under the following conditions: (A) EPCs in monoculture; (B) EPCs 
cocultured with RAW 264.7 macrophages in the absence of nanospheres and without stimuli; (C) 
EPCs cocultured with M2d angiogenic macrophages obtained from RAW 264.7 macrophages 
treated with 1 μM NECA and 100 ng/mL of E. coli LPS; (D) EPCs cocultured with RAW 264.7 mac-
rophages in the presence of 50 μg/mL of NanoMBGs; (E) EPCs cocultured with RAW 264.7 macro-
phages in the presence of 50 μg/mL of NanoMBG-IPs. Statistical significance: ### p < 0.005, ## p < 
0.01 (comparisons with EPC RAW). 
The presence of either NanoMBGs or NanoMBG-IPs in the EPC/RAW coculture in-
duced pronounced and significant increases in the percentage of VEGFR2+ EPCs, in agree-
ment with results obtained with monocultured EPCs (Figure 5). Again, these data demon-
strate the angiogenic effect of this nanomaterial, regardless of the presence of ipriflavone. 
A nonsignificant increase was observed in the presence of NanoMBG-IPs compared to 
NanoMBG; however, it appears that, under these coculture conditions, the action of the 
drug is masked due to the presence of macrophages in the coculture, which also incorpo-
rate the nanospheres and do not allow the effect of the drug to be appreciated. Under 
these experimental conditions, only the angiogenic effect of the nanomaterial itself is evi-
dent. These results are in agreement with the data in Figure 5, which shows a similar effect 
of the conditioned media from macrophages previously treated with both NanoMBGs and 
NanoMBG-IPs on VEGFR2 expression in EPCs, thus indicating that the presence of the 
drug in the nanospheres does not change the effect of macrophages on VEGFR2 expres-
sion by EPCs. 
Figure 7 shows the effect of NanoMBGs and NanoMBG-IPs on CD206 expression in 
RAW 264.7 macrophages cocultured with EPCs. Although coculture of EPCs with control 
RAW macrophages did not induce changes in the percentage of CD206+ macrophages, 
when EPCs were cocultured with M2d angiogenic macrophages, a significant increase in 
this parameter was observed when compared to monocultured control RAW 264.7 cells. 
This result is consistent with the role of CD206 as a specific marker for M2 macrophage 
phenotype [40]. On the other hand, the presence of NanoMBGs without IP in the 
RAW/EPC coculture induced a significant increase of the percentage of CD206+ macro-
phages when compared to control RAW 264.7 cells in monoculture and in coculture with 
EPCs according to previous studies [23]. The treatment of RAW/EPC cocultures with Na-
noMBG-IPs also produced an increase in the CD206+ percentage, but this was not statisti-
cally significant, thus revealing that it is the nanomaterial itself, and not the drug, which 
Figure 6. Effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs) on
VEGFR2 expression in EPCs cocultured with RAW 264.7 macrophages. Percentages of VEGFR2+
EPCs after 7 days under the following conditions: (A) EPCs in monoculture; (B) EPCs cocultured with
RAW 264.7 macrophages in the absence of nanospheres and without stimuli; (C) EPCs cocultured
with M2d angiogenic macrophages obtained from RAW 264.7 macrophages treated with 1 µM NECA
and 100 ng/mL of . coli LPS; (D) EPCs cocultured with RAW 264.7 macrophages in the presence
of 50 µg/mL of NanoMBGs; (E) EPCs cocultured with RAW 264.7 macrophages in the presence of
50 µg/mL of NanoMBG-IPs. Statistical significance: ### p < 0.005, ## p < 0.01 (comparisons with
EPC RAW).
Figure 7 shows the effect of NanoMBGs and NanoMBG-IPs on CD206 expression in
RAW 264.7 macrophages cocultured with EPCs. Although coculture of EPCs with control
RAW macrophages did not induce changes in the percentage of CD206+ m crophages,
when EPCs wer cocultured with M2d angiogenic macrophages, a sig ificant increase in
this parameter was obs rved when compared to mo ocultured control RAW 264.7 cells.
This result is consistent with the role of CD206 as a specific marker for M2 macrophage
phenotype [40]. On he othe ha d, the presence of Na oMBGs without IP in the RAW/EPC
coculture induced a significa t increase of the percentage of CD206+ macrophages wh n
compared to control RAW 264.7 cells in mon cultur and in coculture wi h EPCs according
to previous st dies [23]. Th treatment of RAW/EPC cocultures wit NanoMBG-IPs also
produce an increase n the CD206+ percentage, but this was no statistic lly significant,
thus revealing that it is th nanomaterial itself, and not the drug, which induces is
marker increase in macrophages. Although the benefici l role of ipriflavone preventing
osteoporosi has been evidenced [23–25], data on the effects of this drug on macrophages
are very scarce. Thus, even when flavonoids can inhibit enzymes or transcription factors
relevant in inflammation processes [52], Masilamani et al. indicated that ipriflavone had
no effect in the suppression of effector cells of allergies [53]. Further studies are needed to
understand how ipriflavone acts on macrophages and other cell types.
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Figure 7. Effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs) 
on CD206 expression in RAW 264.7 macrophages cocultured with EPCs. Percentages of CD206+ 
macrophages after 7 days under the following conditions: (A) RAW 264.7 macrophages in mono-
culture; (B) RAW 264.7 macrophages cocultured with EPCs in the absence of nanospheres and 
without stimuli; (C) M2d angiogenic macrophages obtained from RAW 264.7 macrophages treated 
with 1 μM NECA and 100 ng/mL of E. coli LPS and cocultured with EPCs; (D) RAW 264.7 macro-
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phages cocultured with EPCs in the presence of 50 μg/mL of NanoMBG-IPs. Statistical signifi-
cance: ** p < 0.01 (comparisons with control RAW cells in monoculture). 
4. Conclusions 
Our study evidences the great potential of unloaded and ipriflavone-loaded meso-
porous nanospheres to promote the expression of VEGFR2, directly related to angiogene-
sis, after their incorporation by endothelial progenitor cells (EPCs). The pathways in-
volved in the entry of these nanospheres into EPCs include clathrin-dependent endocyto-
sis, as the main entry mechanism, as well as phagocytosis and caveolae-mediated uptake. 
The treatment of EPCs with culture media from basal, M1, and M2 macrophages and stud-
ies with cocultures of EPCs with macrophages in the absence and presence of these nano-
materials confirmed the maintenance of their angiogenic effect on EPCs even in the pres-
ence of phagocytic cells. Further studies with in vivo models will be conducted to deter-
mine the benefits of these nanospheres for bone tissue regeneration via induction of both 
osteogenesis and angiogenesis. 
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Figure 7. Effects of unloaded (NanoMBGs) and ipriflavone-loaded nanospheres (NanoMBG-IPs)
on CD206 expression in RAW 264.7 macrophages cocultured with EPCs. Percentages of CD206+
macrophages after 7 days under the following conditions: (A) RAW 264.7 macrophages in monocul-
ture; (B) RAW 264.7 macr phages cocultured with EPCs i the absence of nanospheres and without
stimuli; (C) M2d angiogenic macrophages obtained from RAW 264.7 macroph g s treated with
1 µM NECA and 100 ng/mL of E. coli LPS and cocultured with EPCs; (D) RAW 264.7 macrophages
cocultured with EPCs in the presence of 50 µg/mL of NanoMBGs; (E) RAW 264.7 macrophages co-
cultured with EPCs in the presence of 50 µg/mL of NanoMBG-IPs. Statistical significance: ** p < 0.01
(comparisons with control RAW cells in monoculture).
4. Conclusions
Our study evid nces the great potential of unloaded a d ipriflavone-loaded meso-
porous nanospheres to promote the expression of VEGFR2, directly related to angiogenesis,
after their incorporation by ndothelial pr genitor cells (EPCs). The pathways involved
in the entry of these nanospheres into EPCs in ude clathrin- pendent endocytosis, as
the main entry mechanism, as well as phagocytosis and caveolae-mediated uptake. The
treatment of EPCs with culture media from b sal, 1, and M2 macrophages and studies
with coculture of EPCs with macrophages in the absence and presence of these nanomate-
rials confirmed the maintenanc of their angiogenic effect on EPCs even in the presence of
phagocytic cells. Fu ther studies with n viv models will be conduc ed to determine the
b nefits of th se anosph res for bone tissue regeneration via induction of both osteogene-
sis and angiogene is.
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